RARE DISEASERESEARCH ATLAS

ORPHA:238459

SLC35A1-CDG

low confidenceDisorder

Also known as: CMP-sialic acid transporter deficiency · Carbohydrate deficient glycoprotein syndrome type IIf · Congenital disorder of glycosylation type 2f · Congenital disorder of glycosylation type IIf · CDG syndrome type IIf · CDG-IIf · CDG2F

Publications

12,996

Trials

0

Interventional, condition-specific

Researchers

429

Distinct authors in sample

Gene link

SLC35A1

Strong

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

SLC35A1-CDG is an extremely rare form of CDG syndrome characterized clinically in the single reported case by repeated hemorrhagic incidents, including severe pulmonary hemorrhage.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (4)

SLC35A1-congenital disorder of glycosylation · carbohydrate deficient glycoprotein syndrome type IIf · congenital disorder of glycosylation type 2f · congenital disorder of glycosylation type IIf

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Strong — SLC35A1

  2. LiteraturePresent

    12,996 matched papers (11,362 in last 10 years) Source

  3. Phenotype characterisedPresent

    41 HPO annotations (e.g. Encephalopathy; Poor speech; Nystagmus) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (SLC35A1).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

41

Associated phenotypes · MONDO:0011342

  • Encephalopathy
  • Poor speech
  • Nystagmus
  • Clinodactyly
  • Intellectual disability

Showing 5 of 41 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

12,996

12,996 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

12,996 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

11,362 in the last 10 years · low confidence

Phrase hits: 78 · MeSH hits: 2

Open Europe PMC search

Who's working on it?

429

Distinct author names in 78 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Lefeber DJ10 papers · 2026

    United for Metabolic Diseases, Amsterdam, Netherlands.

    Papers in Europe PMC
  2. 02
    Morava E10 papers · 2025

    Metabolic Center, Department of Pediatrics, University Hospitals Leuven, Herestraat 49, B-3000, Leuven, Belgium. Morava-Kozicz.Eva@MAYO.edu.

    Papers in Europe PMC
  3. 03
    Jaeken J8 papers · 2026

    Metabolic Center, Department of Pediatrics, University Hospitals Leuven, Herestraat 49, B-3000, Leuven, Belgium.

    Papers in Europe PMC
  4. 04
    Freeze HH7 papers · 2024

    Genetic Disease Program, Sanford Children's Health Research Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, USA. hudson@sanfordburnham.org

    Papers in Europe PMC
  5. 05
    Ng BG5 papers · 2024

    Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.

    Papers in Europe PMC
  6. 06
    Ferreira CR4 papers · 2026

    Medical Genetics Branch National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.

    Papers in Europe PMC
  7. 07
    Li Y4 papers · 2025

    Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Suzhou, China.

    Papers in Europe PMC
  8. 08
    van Scherpenzeel M3 papers · 2020

    Translational Metabolic Laboratory, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Geert Grooteplein 10, Nijmegen, 6525 DA, The Netherlands. Monique.vanScherpenzeel@radboudumc.nl.

    Papers in Europe PMC
  9. 09
    Wada Y3 papers · 2025

    Department of Obstetric Medicine, Osaka Women's and Children's Hospital (OWCH), 840 Murodo-cho, Izumi, Osaka 594-1101, Japan.

    Papers in Europe PMC
  10. 10
    Witters P3 papers · 2025

    Metabolic Center, University Hospitals Leuven, Leuven, Belgium.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

low confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for SLC35A1-CDG — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("SLC35A1-CDG" OR "CMP-sialic acid transporter deficiency" OR "Carbohydrate deficient glycoprotein syndrome type IIf" OR "Congenital disorder of glycosylation type 2f" OR "Congenital disorder of the glycosylation type 2f" OR "Congenital disorder of glycosylation type IIf" OR "Congenital disorder of the glycosylation type IIf" OR "CDG syndrome type IIf" OR "CDG-IIf" OR "CDG2F" OR "SLC35A1-congenital disorder of glycosylation" OR "SLC35A1-congenital disorder of the glycosylation") OR (MESH:"Congenital Disorder Of Glycosylation, Type IIF") OR ("SLC35A1" OR "SLC35A1 syndrome" OR "SLC35A1-related")

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Congenital Disorder Of Glycosylation, Type IIF

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"SLC35A1-CDG" OR "CMP-sialic acid transporter deficiency" OR "Carbohydrate deficient glycoprotein syndrome type IIf" OR "Congenital disorder of glycosylation type 2f" OR "Congenital disorder of the glycosylation type 2f" OR "Congenital disorder of glycosylation type IIf" OR "Congenital disorder of the glycosylation type IIf" OR "CDG syndrome type IIf" OR "CDG-IIf" OR "CDG2F" OR "SLC35A1-congenital disorder of glycosylation" OR "SLC35A1-congenital disorder of the glycosylation" OR "Congenital Disorder Of Glycosylation, Type IIF"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is short or not clearly distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (12996) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-27T10:22:19.896Z